A Chinese biotech developing a PD-1xVEGF bispecific and other antibody-drug conjugates has secured a nine-figure raise from blue-chip investors.
Shanghai-based Minghui Pharmaceutical raised $131 million in what it called a “pre-IPO” financing, the company announced ...
↧